UPB logo

UPB
Upstream Bio Inc.

267
Mkt Cap
$511.55M
Volume
489,698.00
52W High
$33.68
52W Low
$7.25
PE Ratio
-3.53
UPB Fundamentals
Price
$9.40
Prev Close
$9.18
Open
$9.25
50D MA
$9.03
Beta
1.21
Avg. Volume
577,555.10
EPS (Annual)
-$2.66
P/B
1.50
Rev/Employee
$38,053.33
$1,121.86
Loading...
Loading...
News
all
press releases
Alnylam Pharmaceuticals (ALNY) Tops Q1 Earnings and Revenue Estimates
Alnylam (ALNY) delivered earnings and revenue surprises of +39.00% and +2.91%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2d ago
News Placeholder
More News
News Placeholder
Upstream Bio (UPB) to Release Quarterly Earnings on Tuesday
Upstream Bio (NASDAQ:UPB) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 5. (View Earnings Report at...
MarketBeat·4d ago
News Placeholder
Upstream Bio, Inc. (NASDAQ:UPB) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Upstream Bio, Inc. (NASDAQ:UPB - Get Free Report) has been given an average rating of "Moderate Buy" by the five analysts that are covering the company, MarketBeat.com reports. One research analyst...
MarketBeat·10d ago
News Placeholder
Upstream Bio, Inc. (NASDAQ:UPB) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Shares of Upstream Bio, Inc. (NASDAQ:UPB - Get Free Report) have earned an average recommendation of "Moderate Buy" from the five ratings firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, two h...
MarketBeat·1mo ago
News Placeholder
Upstream Bio (NASDAQ:UPB) Rating Lowered to Sell at Wall Street Zen
Wall Street Zen lowered shares of Upstream Bio from a "hold" rating to a "sell" rating in a research note on Saturday...
MarketBeat·1mo ago
News Placeholder
Upstream Bio (NASDAQ:UPB) Downgraded by Evercore to In-Line
Evercore downgraded shares of Upstream Bio from an "outperform" rating to an "in-line" rating and set a $15.00 target price on the stock. in a research note on Friday...
MarketBeat·1mo ago
News Placeholder
Upstream Bio Lead Drug Pivotal Trial Plan Follows Strong Phase 2 Data
Upstream Bio outlines Phase 3 plans for verekitug as asthma and CRSwNP data support dosing strategy; shares rise on update.read more...
Benzinga·1mo ago
News Placeholder
Upstream Bio (NASDAQ:UPB) Posts Earnings Results, Misses Estimates By $0.06 EPS
Upstream Bio (NASDAQ:UPB - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.06). The company had revenue of $0.67 million for the quarter, compared to analyst...
MarketBeat·1mo ago
News Placeholder
Upstream Bio (NASDAQ:UPB) Trading Up 11.2% - What's Next?
Upstream Bio (NASDAQ:UPB) Stock Price Up 11.2% - Here's Why...
MarketBeat·1mo ago
News Placeholder
Upstream Bio (NASDAQ:UPB) Trading 14.4% Higher - Should You Buy?
Upstream Bio (NASDAQ:UPB) Stock Price Up 14.4% - What's Next...
MarketBeat·2mo ago
<
1
2
...
>

Latest UPB News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.